Erasca, Inc. (ERAS)
- Sector
- Biotechnology
- Last price
- $14.78
- As of
Kresmion compiles this page from ERAS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Erasca, Inc. (ERAS): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-24.
See the full ERAS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ERAS on one page. Preview it with sample data, then open it live with a free account.
Preview the ERAS dossierActive signals for ERAS
- highCONSENSUS_BUY
5 tracked funds increased ERAS this 2026Q2, institutional consensus
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 34.7%, EPS $-0.14 vs $-0.1039 estimate
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 77% of ERAS (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of ERAS (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 63% of ERAS (2026Q2)
FREE, NO ACCOUNT
Every signal on ERAS, as it fires
You are seeing 5 of 18 signals recorded on ERAS since 2026-05-30.
The five above landed across 3 days. The other 13 were recorded on 2 other days. 11 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ERAS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29479A108 · 2026Q2 | $25.1M | 0.03% | , |
| Point72 Asset Management, L.P.CUSIP 29479A108 · 2026Q2 | $22.8M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 29479A108 · 2026Q2 | $17.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 29479A108 · 2026Q2 | $16.7M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 29479A108 · 2026Q2 | $1.7M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29479A108 · 2026Q2 | $657K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ERAS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ERAS against its peers
ERAS's return on equity of -38.3% ranks in the 37th percentile of 22 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ERAS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 227M | n/a | 16 |
| Operating margin | n/a | -70.8% | n/a | 14 |
| Net margin | n/a | -72.0% | n/a | 14 |
| Return on equity | -38.3% | -32.5% | 37 | 22 |
| 1 year | 515.8% | 69.4% | 88 | 20 |
Peers (24): MIRM, CGON, MANE, ORKA, PTCT, COGT, APLS, LGND, CRSP, SRRK, BLTE, GRAL, RYTM, CNTA, IMVT, DFTX, KOD, TVTX, IOVA, ALKS, DNTH, PRAX, EWTX, IONS. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ERAS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ERAS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ERAS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.